-
-
-
-
-
-
-
AbCellera (ABCL) Tops Q1 EPS by 1c
-
-
-
-
-
-
-
AbCellera Reports Full Year 2025 Business Results
-
-
-
-
-
-
-
AbCellera begins dosing ABCL635 in phase 1 trial for menopause symptoms
-
-
-
-
-
-
-
AbCellera (ABCL) reported revenue at $5.1 million
-
-
-
-
-
-
-
AbCellera (ABCL) Tops Q2 EPS by 1c
-
-
-
-
-
-
-
Benchmark Upgrades AbCellera Biologics (ABCL) to Buy, 'R&D Progress Highlights 4Q23'
-
-
-
-
-
-
-
AbCellera (ABCL) Tops Q2 EPS by 11c
-
1,222,715 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

